Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alexandra Frelau1, Marc Pracht1, Samuel Le Sourd1

  • 1CLCC Eugène-Marquis UNICANCER, oncologie médicale, avenue de la Bataille-Flandres-Dunkerque, 35042 Rennes cedex, France.

Bulletin Du Cancer
|January 1, 2019
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antiangiogenic therapies in gastric cancer: future directions for 2026 and beyond: an UNICANCER gastrointestinal group (UCGI) perspective.

Cancer treatment reviews·2026
Same author

Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial.

The lancet. Gastroenterology & hepatology·2026
Same author

Prevalence of homologous recombination repair genes alterations in metastatic castration-resistant prostate cancer, a multicentric study.

The French journal of urology·2026
Same author

Second-Line Practices in the Era of Immunotherapy in HCC: The CHIEF Cohort.

JHEP reports : innovation in hepatology·2026
Same author

Technical recommendations from a large-scale French Delphi consensus: A step toward European harmonization of ctDNA analysis.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Second-line TKI after first-line immunotherapy-based treatment in advanced HCC: Reconstructed IPD meta-analysis.

JHEP reports : innovation in hepatology·2026
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
Same journal

[Reirradiation: A new therapeutic paradigm in oncology].

Bulletin du cancer·2026
See all related articles
This summary is machine-generated.

Identifying predictive biomarkers for immune checkpoint inhibitors is crucial for cancer treatment. While PD-L1 expression and tumor mutation burden show promise, none are fully validated for predicting response to PD-1 inhibitors.

Area of Science:

  • Oncology
  • Immunology
  • Biomarker Discovery

Background:

  • Immune checkpoint inhibitors targeting PD-1 are a key cancer therapy.
  • Patient responses to PD-1 inhibitors vary significantly.
  • Identifying reliable biomarkers is essential to predict treatment efficacy.

Purpose of the Study:

  • To review potential biomarkers for predicting response to PD-1 checkpoint inhibitors.
  • To evaluate the current evidence for various predictive biomarkers.

Main Methods:

  • Literature review of studies on predictive biomarkers for PD-1 inhibitors.
  • Analysis of data on PD-L1 expression, neutrophil-to-lymphocyte ratio, neoantigen load, mutation burden, genetic signatures, gut microbiota, and cytokines.

Main Results:

Keywords:
Anti-PD1BiomarkersBiomarqueursExpression de PD-L1ImmunotherapyImmunothérapiePD-1 blockadesPD-L1 expression

Related Experiment Videos

  • PD-L1 expression is a potential biomarker but lacks standardization and shows heterogeneity.
  • Neutrophil-to-lymphocyte ratio, high neoantigen load, and microsatellite instability are associated with better response.
  • Genetic signatures, gut microbiota, and cytokines may also serve as predictive biomarkers.

Conclusions:

  • Several promising biomarkers for PD-1 inhibitor response exist, including PD-L1, mutation burden, and gut microbiota.
  • None of the identified biomarkers have been prospectively validated to date.
  • Further research is needed to validate these biomarkers for clinical application.